A Multicentre Randomised Phase II Study of mFOLFOXIRI Versus mFOLFOX6 in Combination With Bevacizumab or Cetuximab as First-Line Treatment for Patients With Metastatic Colorectal Cancer

ABSTRACT: Interventions: experimental group:mFOLFOXIRI combined with Bevacizumab/Cetuximab;control group:mFOLFOX6 combined with Bevacizumab/Cetuximab Primary outcome(s): objective response rate Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2698636 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR